Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis

Kunal Dhiman, Kaj Blennow, Henrik Zetterberg, Ralph N. Martins, Veer Bala Gupta

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is a multifactorial age-related brain disease. Numerous pathological events run forth in the brain leading to AD. There is an initial long, dormant phase before the clinical symptoms become evident. There is a need to diagnose the disease at the preclinical stage since therapeutic interventions are most likely to be effective if initiated early. Undoubtedly, the core cerebrospinal fluid (CSF) biomarkers have a good diagnostic accuracy and have been used in clinical trials as end point measures. However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology. The review is focused upon a panel of biomarkers that relate to different aspects of AD pathology, as well as various studies that have evaluated their diagnostic potential. The panel includes markers of neurodegeneration: neurofilament light chain and visinin-like protein (VILIP-1); markers of amyloidogenesis and brain amyloidosis: apolipoproteins; markers of inflammation: YKL-40 and monocyte chemoattractant protein 1; marker of synaptic dysfunction: neurogranin. These markers can highlight on the state and stage-associated changes that occur in AD brain with disease progression. A combination of these biomarkers would not only aid in preclinical diagnosis, but would also help in identifying early brain changes during the onset of disease. Successful treatment strategies can be devised by understanding the contribution of these markers in different aspects of disease pathogenesis.

Original languageEnglish
Pages (from-to)1833-1863
Number of pages31
JournalCellular and Molecular Life Sciences
Volume76
Issue number10
DOIs
Publication statusPublished - 30 May 2019

Fingerprint

Cerebrospinal Fluid
Alzheimer Disease
Biomarkers
Brain Diseases
Pathology
Neurocalcin
Neurogranin
Brain
Intermediate Filaments
Apolipoproteins
Chemokine CCL2
Amyloidosis
Dementia
Disease Progression
Clinical Trials
Inflammation
Light
Therapeutics

Cite this

Dhiman, Kunal ; Blennow, Kaj ; Zetterberg, Henrik ; Martins, Ralph N. ; Gupta, Veer Bala. / Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis. In: Cellular and Molecular Life Sciences. 2019 ; Vol. 76, No. 10. pp. 1833-1863.
@article{0e39063bc8e14cd592515586932e0e19,
title = "Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis",
abstract = "Alzheimer’s disease (AD) is a multifactorial age-related brain disease. Numerous pathological events run forth in the brain leading to AD. There is an initial long, dormant phase before the clinical symptoms become evident. There is a need to diagnose the disease at the preclinical stage since therapeutic interventions are most likely to be effective if initiated early. Undoubtedly, the core cerebrospinal fluid (CSF) biomarkers have a good diagnostic accuracy and have been used in clinical trials as end point measures. However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology. The review is focused upon a panel of biomarkers that relate to different aspects of AD pathology, as well as various studies that have evaluated their diagnostic potential. The panel includes markers of neurodegeneration: neurofilament light chain and visinin-like protein (VILIP-1); markers of amyloidogenesis and brain amyloidosis: apolipoproteins; markers of inflammation: YKL-40 and monocyte chemoattractant protein 1; marker of synaptic dysfunction: neurogranin. These markers can highlight on the state and stage-associated changes that occur in AD brain with disease progression. A combination of these biomarkers would not only aid in preclinical diagnosis, but would also help in identifying early brain changes during the onset of disease. Successful treatment strategies can be devised by understanding the contribution of these markers in different aspects of disease pathogenesis.",
keywords = "Diagnosis, Fatty acid-binding proteins, Neurodegeneration, Neurofilament light, Neurogranin, Neuroinflammation, Synaptic dysfunction",
author = "Kunal Dhiman and Kaj Blennow and Henrik Zetterberg and Martins, {Ralph N.} and Gupta, {Veer Bala}",
year = "2019",
month = "5",
day = "30",
doi = "10.1007/s00018-019-03040-5",
language = "English",
volume = "76",
pages = "1833--1863",
journal = "Cellular and Molecular Life Sciences",
issn = "1420-682X",
publisher = "Birkhauser Verlag Basel",
number = "10",

}

Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis. / Dhiman, Kunal; Blennow, Kaj; Zetterberg, Henrik; Martins, Ralph N.; Gupta, Veer Bala.

In: Cellular and Molecular Life Sciences, Vol. 76, No. 10, 30.05.2019, p. 1833-1863.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer’s disease pathogenesis

AU - Dhiman, Kunal

AU - Blennow, Kaj

AU - Zetterberg, Henrik

AU - Martins, Ralph N.

AU - Gupta, Veer Bala

PY - 2019/5/30

Y1 - 2019/5/30

N2 - Alzheimer’s disease (AD) is a multifactorial age-related brain disease. Numerous pathological events run forth in the brain leading to AD. There is an initial long, dormant phase before the clinical symptoms become evident. There is a need to diagnose the disease at the preclinical stage since therapeutic interventions are most likely to be effective if initiated early. Undoubtedly, the core cerebrospinal fluid (CSF) biomarkers have a good diagnostic accuracy and have been used in clinical trials as end point measures. However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology. The review is focused upon a panel of biomarkers that relate to different aspects of AD pathology, as well as various studies that have evaluated their diagnostic potential. The panel includes markers of neurodegeneration: neurofilament light chain and visinin-like protein (VILIP-1); markers of amyloidogenesis and brain amyloidosis: apolipoproteins; markers of inflammation: YKL-40 and monocyte chemoattractant protein 1; marker of synaptic dysfunction: neurogranin. These markers can highlight on the state and stage-associated changes that occur in AD brain with disease progression. A combination of these biomarkers would not only aid in preclinical diagnosis, but would also help in identifying early brain changes during the onset of disease. Successful treatment strategies can be devised by understanding the contribution of these markers in different aspects of disease pathogenesis.

AB - Alzheimer’s disease (AD) is a multifactorial age-related brain disease. Numerous pathological events run forth in the brain leading to AD. There is an initial long, dormant phase before the clinical symptoms become evident. There is a need to diagnose the disease at the preclinical stage since therapeutic interventions are most likely to be effective if initiated early. Undoubtedly, the core cerebrospinal fluid (CSF) biomarkers have a good diagnostic accuracy and have been used in clinical trials as end point measures. However, looking into the multifactorial nature of AD and the overlapping pathology with other forms of dementia, it is important to integrate the core CSF biomarkers with a broader panel of other biomarkers reflecting different aspects of pathology. The review is focused upon a panel of biomarkers that relate to different aspects of AD pathology, as well as various studies that have evaluated their diagnostic potential. The panel includes markers of neurodegeneration: neurofilament light chain and visinin-like protein (VILIP-1); markers of amyloidogenesis and brain amyloidosis: apolipoproteins; markers of inflammation: YKL-40 and monocyte chemoattractant protein 1; marker of synaptic dysfunction: neurogranin. These markers can highlight on the state and stage-associated changes that occur in AD brain with disease progression. A combination of these biomarkers would not only aid in preclinical diagnosis, but would also help in identifying early brain changes during the onset of disease. Successful treatment strategies can be devised by understanding the contribution of these markers in different aspects of disease pathogenesis.

KW - Diagnosis

KW - Fatty acid-binding proteins

KW - Neurodegeneration

KW - Neurofilament light

KW - Neurogranin

KW - Neuroinflammation

KW - Synaptic dysfunction

UR - http://www.scopus.com/inward/record.url?scp=85061706457&partnerID=8YFLogxK

U2 - 10.1007/s00018-019-03040-5

DO - 10.1007/s00018-019-03040-5

M3 - Review article

VL - 76

SP - 1833

EP - 1863

JO - Cellular and Molecular Life Sciences

JF - Cellular and Molecular Life Sciences

SN - 1420-682X

IS - 10

ER -